GTx Muscle Wasting Drug Fails, But Data Offer Possible New Path
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Enobosarm failed under FDA analysis plan but met European requirements in NSCLC muscle wasting trials, while a potential survival signal may lead to a positive change of plans in the U.S.